- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02387905
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery: A Randomized Phase II Clinical Trial
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To assess whether prophylactic cement augmentation reduces new or progressive vertebral body fracture at 3 months in high risk patients undergoing single fraction spine stereotactic radiosurgery.
SECONDARY OBJECTIVES:
I. To assess the impact of prophylactic cement augmentation on time to first new or progressive vertebral body fracture.
II. To assess the impact of prophylactic cement augmentation on pain control measured every three months post treatment.
III. To assess the impact of prophylactic cement augmentation on quality of life measured every three months post treatment.
IV. To estimate local control in each arm. V. To estimate overall survival in each arm. VI. To document and assess post-treatment adverse side effects between the two arms.
VI. To document and assess the relationship between radiographic vertebral body fracture, pain control and quality of life.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo stereotactic spinal radiosurgery per standard of care.
ARM II: Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Amol Ghia
- Phone Number: 713-563-2300
- Email: ajghia@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients must have histologic proof of solid tumor malignancy and radiographic evidence of spine metastasis
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 3 months
- All patients must be able to lie supine
- All patients must have no more than 3 contiguous vertebral body levels treated at a single site, and no more than 3 discontiguous vertebral body levels treated
- All patients must have a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gray (Gy)
All patients must be deemed at "high risk" of developing vertebral body fracture by having at least one of the following characteristics:
- Spine Instability Neoplastic Score classification of "Indeterminate" deemed as a score from 7 to 12
- Pre-existing vertebral body fracture
- Planned radiation dose of 24 Gy
- All patients must have a vertebral body site to be treated located from T1 to L5
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- All patients must sign informed consent verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of M.D. Anderson Cancer Center; the only acceptable consent is the one approved by M.D. Anderson Institutional Review Board (IRB)
- Patients undergoing bisphosphonate therapy are allowed
Exclusion Criteria:
- Patients who have had prior radiotherapy at the spine site and level to be treated
- Patients who have had prior surgery at the spine level to be treated to include prior cement augmentation, laminectomy, vertebrectomy, tumor debulking, instrumentation
- Patients with gross disease involving only the posterior elements
- Patients who have > 50% vertebral body collapse
- Patients unable to undergo magnetic resonance imaging (MRI) of the spine
- Patents with cord compression
- Patients deemed not be a candidate for cement augmentation for any reason
- Patients who have frank mechanical pain
- Patients with both pedicles involved with gross disease at the level of potential cement augmentation
- Pregnant women are excluded from this study
- Patients with a histology of lymphoma, myeloma and small cell lung cancer histologies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (standard of care)
Patients undergo stereotactic spinal radiosurgery per standard of care.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo standard stereotactic spinal radiosurgery
Other Names:
|
Experimental: Arm II (vertebral body cement augmentation)
Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo standard stereotactic spinal radiosurgery
Other Names:
Undergo vertebral body cement augmentation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vertebral compression fracture rate
Time Frame: At 3 months
|
Will compare the 3-month vertebral compression fracture proportions between treatment groups using the Fisher exact test.
Will be performed on the intention-to-treat principle.
|
At 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first new or progressive vertebral body fracture
Time Frame: Up to 2 years
|
To assess the impact of prophylactic cement augmentation on time to first new or progressive vertebral body fracture, will use the Kaplan-Meier method to estimate the freedom from fracture curves and Cox proportional hazards regression analysis to estimate the hazard ratio with confidence intervals and associated p-values.
|
Up to 2 years
|
Pain control, assessed using the Brief Pain Inventory form
Time Frame: Up to 2 years
|
Will use mixed effects linear models to analyze this longitudinal data.
|
Up to 2 years
|
Quality of life, assessed using the MD Anderson Symptom Inventory-Spine Tumor form
Time Frame: Up to 2 years
|
Participants are asked to recall symptom severity and interference during the past 24 hours.
Part I, The severity of the symptoms, including pain, fatigue, nausea, disturbed sleep, short of breath etc.
Part II, How have the symptoms interfered with patient life, including mood, work, relations with other people etc. Part I, range 0-10.
A score of 0 would mean the symptom is not present and a score of 10 means the symptom is as bad as you can imagine).
Part II, range 0-10 (A score of 0 would mean the symptom did not interfere; A score of 10 means the symptom has interfered completely.
The ratings in the MDASI can be averaged into several subscale scores: mean core symptom severity, mean module symptom severity, mean total symptom severity, and mean interference.
The interference items can further be broken down into mean activity interference and mean affective interference.
Symptom items may be presented individually
|
Up to 2 years
|
Local control
Time Frame: Up to 2 years
|
Will estimate time to first local failure curves using the Kaplan-Meier method.
|
Up to 2 years
|
Overall survival
Time Frame: Up to 2 years
|
Will use the Kaplan-Meier method.
|
Up to 2 years
|
Incidence of post-treatment adverse events
Time Frame: Up to 2 years
|
Will estimate the difference in grade 3+ toxicity rates, with 95% confidence intervals and a chi-squared test p-value.
|
Up to 2 years
|
Radiographic vertebral body fracture, pain control and quality of life assessment
Time Frame: Up to 2 years
|
Will assess the relationship between radiographic vertebral body fracture, pain control and quality of life using correlation analyses.
Additional analyses may be conducted as appropriate.
|
Up to 2 years
|
Quality of life, assessed using the EuroQol 5-dimensional 5-level questionnaire.
Time Frame: Up to 2 years
|
Will use mixed effects linear models to analyze this longitudinal data. The questionnaire consists 2 parts. Part 1 is descriptive system (participants are asked mobility, self-care status, usual activities, pain/discomfort, anxiety/depression, and each dimension has 5 levels; Part 2 is the Visual analogue scale (the self-rated health today with score 0-100; 100 means the best health you can imagine. 0 means the worst health you can imagine) Part 2, participants give self-rated health today with 100 means the best health you can imagine. 0 means the worst health you can imagine. Part 2, higher range represents a better outcome |
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amol J Ghia, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-0561 (Other Identifier: M D Anderson Cancer Center)
- NCI-2015-00494 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Malignant Solid Neoplasm
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Puerto Rico
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States